Denali Therapeutics: T. Rowe Price reports 12.3% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Denali Therapeutics Inc. (DNLI) is the issuer in an amended common-stock ownership report by T. Rowe Price Investment Management, Inc. The investment manager reported 19,634,011 shares, equal to 12.3% of the class, and sole voting power over 18,904,392 shares; it reported sole dispositive power over 19,634,011 shares, with no shared voting or dispositive power. The report identifies September 30, 2026, as the event date and states that its filing is not an admission of beneficial ownership, which the investment manager expressly denies.
Key Figures
Key Terms
beneficially owned regulatory
dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.